Study of Fibroepithelial Lesions of Breast at a tertiary Care Centre- an Audit, Clinicopathological APPROACH and Comparison with WHO Grading | Chapter 14 | New Frontiers in Medicine and Medical Research Vol. 1

 Background: From indolent fibroadenoma to the potentially lethal phyllodes tumour, mammary fibroepithelial lesions include a wide range of cancers (PT). The morphological classification criteria are often difficult to apply, and there is no consensus on what constitutes a suitable resection margin. The current study's goals were to look into the histopathological spectrum of breast fibroepithelial lesions in a tertiary care setting, stratify and classify various fibroepithelial lesions into fibroadenomas and PT, and reclassify all confirmed cases of PT seen during the study period using standard histopathological WHO criteria.

Methods: Records and slides of fibroepithelial lesions of the breast received at the department were retrieved and reviewed between January 2016 and August 2019.

891 fibroepithelial lesions of the breast were found throughout this time. There were 826 cases of fibroadenoma and its variants (92.7%), 34 cases of fibroadenomatoid mastopathy (3.8%), and 31 cases of PT (3.5%). Eight percent (25.8%) of all PT were borderline, four percent (12.9%) were malignant, and the rest (61.3%) were benign.

Conclusions: Breast fibroepithelial tumours are a heterogeneous group of diseases ranging in severity from benign fibroadenoma to malignant PT. The histologic features of several subtypes overlap, and change and progression to a more malignant phenotype are possible. Because there are significant clinical differences between subtypes, accurate pathologic classification is essential for effective therapy. Although some immunohistochemical markers may aid in this differential diagnosis, histomorphology remains the gold standard.

Author (s) Details

Deepti Yadav
Department of Pathology, SMS Medical College, Jaipur, Rajasthan, India.

Mukta Meel
Department of Pathology, SMS Medical College, Jaipur, Rajasthan, India.

Deepika Hemrajani
Department of Pathology, SMS Medical College, Jaipur, Rajasthan, India.

Aarti Mittal
Department of Pathology, SMS Medical College, Jaipur, Rajasthan, India.

Kusum Mathur
Department of Pathology, SMS Medical College, Jaipur, Rajasthan, India.

View Book :- https://stm.bookpi.org/NFMMR-V1/article/view/2793

Fibroadenoma of Ectopic Breast Tissue in Chest Wall: Review of the Literature and Report of a Rare Case | Chapter 9 | Highlights on Medicine and Medical Science Vol. 14

 Ectopic breast tissue fibroadenoma is a rather uncommon condition. Ectopic breast tissues can be detected along the milk line. Malignancy is more prevalent than fibroadenoma in ectopic breast tissue. It's possible to find ectopic breast tissue with or without a nipple areola complex. A 20-year-old woman presented with an ectopic breast tissue fibroadenoma in the anterior chest wall but no nipple areola complex. On the patient, excision and biopsy were conducted. Histopathology confirmed the fibroadenoma of the ectopic breast tissue. Because of its rarity, this case was presented to emphasise the importance of monitoring EBT for any abnormalities as part of routine breast screening.

Author (S) Details

Pradeep Balmiki
Department of Surgery, Atal Bihari Vajpayi Government Medical College, Vidisha, Madhya Pradesh, India.

Kamlesh Mourya
Department of Surgery, Atal Bihari Vajpayi Government Medical College, Vidisha, Madhya Pradesh, India.

View Book :- https://stm.bookpi.org/HMMS-V14/article/view/2560

Study on Resveratrol Chemoprotective Effect and COX 2 Down Regulation in Tumor Suppression in DMBA Induced Breast Cancer in Female Sprague Dawley Rats | Chapter 15 | Technological Innovation in Pharmaceutical Research Vol. 9

Background: The purpose of this study was to see if Resveratrol might help protect female Sprague Dawley rats from developing breast cancer caused by 7,12 Dimethylbenzanthracene (DMBA), as well as if it could help downregulate COX 2, an enzyme seen in breast cancer tissues. Methods: In this investigation, 40 female Sprague Dawley rats (n = 10 per group) were employed. 6 week old rats were divided into four groups: group 1 received pulverised rodent diet, group 2 received DMBA and diet, group 3 received DMBA and diet with Resveratrol 100mcg, and group 4 received DMBA and diet with Resveratrol 100mcg. 200mcg. After 120 days, the study was terminated, and tumours were assessed for multiplicity, incidence, and histology. Cox 2 expression was examined by Western blot analysis. One way variance and Tukey's comparison test were used to test the values statistically. Body weight and tumour volume were similar in the resveratrol-treated groups, and there was a very lengthy latency time for tumour initiation, as well as a reduction in tumour multiplicity and incidence. Group 2 had a tumour incidence of 42.2710.17, Group 3 had a tumour incidence of 21.915.87, and Group 4 had a tumour incidence of 13.733.98. Group 2 had a tumour multiplicity of 0.89090.30, group 3 had a tumour multiplicity of 0.10360.04, and group 4 had a tumour multiplicity of 0.045450.02. In groups 2, 3, and 4, histopathological investigation indicated ductal carcinoma, mild tissue necrosis, and fibroadenoma. Resveratrol reduces COX 2 expression in breast carcinoma and has a chemopreventive impact against DMBA-induced breast cancer, according to the findings.

Author(s) Details

Dr. Aneena Suresh
Department of Pharmacy Practice, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty, Nilgiris, India.

Rajat Rana
Department of Pharmacy Practice, Asmara College of Health Sciences, Asmara, Eritrea.

Keerthana C.
Department of Pharmacy Practice, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty, Nilgiris, Tamil Nadu, India.

View Book :-  https://stm.bookpi.org/TIPR-V9/article/view/2528